By MORGAN WINSOR, ABC News(NEW YORK) — A pandemic of the novel coronavirus has now killed more than 1.3 million people worldwide.Over 57.4 million people across the globe have been diagnosed with COVID-19, the disease caused by the new respiratory virus, according to data compiled by the Center for Systems Science and Engineering at Johns Hopkins University. The actual numbers are believed to be much higher due to testing shortages, many unreported cases and suspicions that some national governments are hiding or downplaying the scope of their outbreaks. The criteria for diagnosis — through clinical means or a lab test — has also varied from country to country.The United States is the worst-affected nation, with more than 11.9 million diagnosed cases and at least 254,383 deaths.Nearly 200 vaccine candidates for COVID-19 are being tracked by the World Health Organization, at least 10 of which are in crucial phase three studies. Of those 10 potential vaccines in late-stage trials, there are currently five that will be available in the United States if approved.Here’s how the news is developing Monday. All times Eastern:Nov 23, 5:39 amUS reports over 142,000 new casesThere were 142,732 new cases of COVID-19 confirmed in the United States on Sunday, according to a real-time count kept by Johns Hopkins University.It’s the 20th straight day that the country has reported over 100,000 newly diagnosed infections. Sunday’s count falls under the all-time high of 196,004 new cases on Nov. 20.An additional 921 fatalities from COVID-19 were also registered nationwide on Sunday, down from a peak of 2,609 new deaths on April 15.A total of 12,247,487 people in the United States have been diagnosed with COVID-19 since the pandemic began, and at least 256,783 of them have died, according to Johns Hopkins. The cases include people from all 50 U.S. states, Washington, D.C. and other U.S. territories as well as repatriated citizens.Much of the country was under lockdown by the end of March as the first wave of the pandemic hit. By May 20, all U.S. states had begun lifting stay-at-home orders and other restrictions put in place to curb the spread of the novel coronavirus. The day-to-day increase in the country’s cases then hovered around 20,000 for a couple of weeks before shooting back up and crossing 100,000 for the first time on Nov. 4.
Nov 23, 4:41 amAstraZeneca, Oxford say their vaccine is up to 90% effectiveU.K.-based pharmaceutical giant AstraZeneca and England’s University of Oxford announced Monday that late-stage trials show their COVID-19 vaccine was up to 90% effective in preventing the disease.The results are based on interim analysis of phase 3 trials in the United Kingdom and Brazil, which looked at two different dosing regimens. One regimen showed vaccine efficacy of 90% when the drug, called AZD1222, was given as a half dose, followed by a full dose at least one month apart. A second regimen showed 62% efficacy when given as two full doses at least one month apart. The combined analysis from both dosing regimens showed an average efficacy of 70%, according to press releases from AstraZeneca and Oxford.There were a total of 131 COVID-19 cases in the analysis, and no hospitalizations or severe cases of the disease were reported in participants receiving the vaccine candidate, according to the press releases.”These findings show that we have an effective vaccine that will save many lives,” Andrew Pollard, director of the Oxford Vaccine Group and chief investigator of the Oxford vaccine trial, said in a statement Monday. “Excitingly, we’ve found that one of our dosing regimens may be around 90% effective and if this dosing regime is used, more people could be vaccinated with planned vaccine supply.”AstraZeneca, which has promised not to profit from the vaccine “for the duration of the pandemic,” said it will now immediately prepare to submit the data to regulators around the world — including in the United Kingdom, Europe and Brazil — that have framework in place for conditional or early approval. The company will also seek an emergency use listing from the World Health Organization for an accelerated pathway to vaccine availability in low-income nations.Meanwhile, Oxford said it is submitting the full analysis of the interim results for independent scientific peer review and publication.”Today marks an important milestone in our fight against the pandemic,” AstraZeneca CEO Pascal Soriot said in a statement Monday. “This vaccine’s efficacy and safety confirm that it will be highly effective against COVID-19 and will have an immediate impact on this public health emergency. Furthermore, the vaccine’s simple supply chain and our no-profit pledge and commitment to broad, equitable and timely access means it will be affordable and globally available, supplying hundreds of millions of doses on approval.”The U.K. government has already placed orders for 100 million doses of the AstraZeneca/Oxford vaccine candidate, along with 40 million doses of another developed by Pfizer and BioNTech which has shown to have 95% efficacy.Copyright © 2020, ABC Audio. All rights reserved.